Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CD7 CAR-T
i
Other names:
CD7 CAR-T
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Hedy Group
Drug class:
CD7-targeted CAR-T immunotherapy
Related drugs:
‹
4SCAR7U (0)
Autologous CAR-T cells (0)
BEAM-201 (0)
BT-007 (0)
CD7 CAR-T Cell (0)
CD7-CAR-T (0)
CD7-UCAR-γδT cells (0)
CTD401 (0)
GC027 (0)
GC502 (0)
RD13-02 (0)
SENL101 (0)
ThisCART7 (0)
WU CART 007 (0)
anti-CD7 CAR-T cell therapy (0)
autologous CD7-CAR T cells (0)
4SCAR7U (0)
Autologous CAR-T cells (0)
BEAM-201 (0)
BT-007 (0)
CD7 CAR-T Cell (0)
CD7-CAR-T (0)
CD7-UCAR-γδT cells (0)
CTD401 (0)
GC027 (0)
GC502 (0)
RD13-02 (0)
SENL101 (0)
ThisCART7 (0)
WU CART 007 (0)
anti-CD7 CAR-T cell therapy (0)
autologous CD7-CAR T cells (0)
›
Associations
News
Trials
Filter by
Latest
over1year
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
P1/2, N=30, Active, not recruiting, Guangzhou Bio-gene Technology Co., Ltd | Recruiting --> Active, not recruiting | Initiation date: Aug 2023 --> May 2023
over 1 year ago
Enrollment closed • Trial initiation date
|
CD7 (CD7 Molecule)
|
CD7 CAR-T
over1year
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
P1/2, N=30, Recruiting, Guangzhou Bio-gene Technology Co., Ltd | Phase classification: P=N/A --> P1/2
over 1 year ago
Phase classification
|
CD7 (CD7 Molecule)
|
CD7 CAR-T
over1year
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
P1/2, N=30, Recruiting, Guangzhou Bio-gene Technology Co., Ltd | Not yet recruiting --> Recruiting
over 1 year ago
Enrollment open
|
CD7 (CD7 Molecule)
|
CD7 CAR-T
over1year
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
P=N/A, N=30, Not yet recruiting, Guangzhou Bio-gene Technology Co., Ltd
over 1 year ago
New P1/2 trial • New trial
|
CD7 (CD7 Molecule)
|
CD7 CAR-T
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login